等待开盘
0.000
NaN.00%
BrightSpring Health Services' Onco360®, a specialty pharmacy, has been selected as a national pharmacy partner for newly approved therapies targeting advanced cancers and rare genetic disorders, including GOMEKLI™ for neurofibromatosis type 1, AVMAPKI™ FAKZYNJA™ CO-PACK for KRAS-mutated ovarian cancer, and IBTROZI™ for ROS1-positive lung cancer.
2025-06-18 20:30
BrightSpring Health Services的股东计划通过二次发行出售总计1400万股普通股,其中包括KKR关联公司和管理层的部分成员。高盛和美国银行证券将担任此次发行的联合簿记管理人。
2025-06-10 20:16